Speech by Chancellor Scholz on the occasion of the groundbreaking ceremony for the Chemical Innovation Plant of Boehringer Ingelheim on May 2, 2023, in Ingelheim am Rhein.

Germany Olaf Scholz · Member of the Bundestag

2 May 2023 · Groundbreaking ceremony for the Chemical Innovation Plant of Boehringer Ingelheim · Ingelheim am Rhein, Germany

Context
Scholz addressed guests at the groundbreaking ceremony for Boehringer Ingelheim's Chemical Innovation Plant in Ingelheim am Rhein on May 2, 2023.
Main themes
Pharmaceutical industry investment in Germany, Boehringer Ingelheim Chemical Innovation Plant, energy security and affordable energy supply, climate neutrality and industrial competitiveness, supply chain resilience for critical medicines, reduction of bureaucracy and accelerated approvals, renewable energy transition, research and development incentives, Germany as an industrial location, Rhineland-Palatinate economic policy
Duration
~9 min
33rd percentile
Words
1,116
33rd percentile
Sentences
67
44th percentile
Readability
37
29th percentile
Grade
12.2
47th percentile
Syntax
2.76
18th percentile
Vocabulary
2.35
83rd percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 56%55%
  • Ceremonial 21%21%
  • Institutional 8%7%
  • Social 5%4%
  • Technological 5%4%
  • Geopolitical 3%3%
  • Environmental 3%3%
  • Not in focus 1%

67 sentences in 23 paragraphs

Dear Mr. von Baumbach,

dear Ms. Nikolaus,

esteemed Minister-President, dear Malu,

esteemed members of parliament,

esteemed district administrator,

honorable mayor,

esteemed Mr. Steutel,

ladies and gentlemen,

above all, dear employees of Boehringer Ingelheim,

there are companies that have become synonymous with the places where they produce. When one thinks of VW, one immediately thinks of Wolfsburg; of BASF, Ludwigshafen; and of Boehringer, of course, Ingelheim. This 138-year symbiosis between company and location is so firmly established and so successful that Boehringer Ingelheim even carries its hometown in its company name.

This brings me to what we are celebrating today. We are celebrating Boehringer Ingelheim's commitment to Germany as a pharmaceutical and chemical location with tradition and future. This is represented by the investments ‑ in the plural ‑ that you are making here in Germany. You already mentioned the inauguration of the Biological Development Center in Biberach last week. It stands for Boehringer's excellence in the field of biotechnology. Congratulations from me as well!

Today, just a few days later, we are laying the foundation stone for the successful future of the pharmaceutical location Ingelheim. You have consciously decided to continue developing and manufacturing chemical active ingredients for your pharmaceuticals here. This secures your company an innovation advantage. This is good for the employees who will be working here in just three years, and it is good for Germany.

The war in Ukraine, the pandemic, and the related problems in global supply chains have shown us one thing: For certain critical products, we must not be dependent on just one or two suppliers. This is especially true for products like yours that heal diseases or alleviate symptoms. That is why the Chemical Innovation Plant being built here in Ingelheim sends such an important signal. That is why it was important for me to be here.

I fully agree with you, esteemed Mr. von Baumbach, when you call for an investment-friendly environment here in Germany. Malu Dreyer has already mentioned how much the state of Rhineland-Palatinate is doing for this: through innovations and research, through the networking of universities and companies, and through a smart location policy. The fact that this pays off ‑ in the truest sense of the word ‑ can be seen not only "At the Gold Mine" in Mainz but has long been evident here at Boehringer Ingelheim.

The federal government also plays its part in such success stories made in Germany. For the chemical industry, it is primarily about energy security and affordable energy supply. Malu Dreyer and I spoke about this in February with the companies based here at the chemical location in Rhineland-Palatinate. Sabine Nikolaus from Boehringer was also present. The commitment I made here in February stands: Yes, we will be climate-neutral by 2045, just like our neighbors, just like many other countries around the world, and at the same time, Germany will remain a leading industrial nation. There is no either-or.

That is why, in recent months, we have rapidly built a completely new import infrastructure for liquefied gas. Energy prices have fallen significantly since then. That is why we have reduced unnecessary bureaucracy, established new area targets for renewable energies, and massively accelerated approval processes. Germany is picking up speed, and anyone who travels around the country can see where investments are currently being made.

I know that Boehringer Ingelheim is already several steps ahead in terms of energy compared to some other companies. Since October 2021, the electricity at your German locations has predominantly come from renewable energies, and with the new biomass power plant that is set to go online here in Ingelheim in early 2024, you will practically become climate-neutral self-sufficient. This is exemplary. It gives hope because it shows: It is possible! Becoming climate-neutral and remaining a successful industrial nation – that is achievable!

We share the goal that important medications and their precursors will continue to be produced here in Germany and Europe. That is why we launched a law in mid-April that provides incentives for the production of supply-critical medicines in Germany and Europe. But equally important is that we want Germany and Europe to remain leading locations for top research and development. This is crucial for a company like yours, which impressively invests billions of euros each year in research and development, and it is crucial for jobs in our country, for our competitiveness, and for good medicine.

To this end, we are creating an attractive environment in Germany. The federal government has already initiated a number of measures to accelerate approval processes. In addition, we are currently examining how we can further improve the speed and cost efficiency of clinical trials. The health minister is also working on a law that will facilitate the use of anonymized health data for research companies like yours. After all, your products ideally save lives, and accordingly, you must advance research quickly, in the interest of us all.

Yes, we will of course closely examine the effects of the GKV Financial Stabilization Act. The pharmaceutical industry has made a significant contribution to the stability of the financing of statutory health insurance. It is important to me that the pharmaceutical industry continues to firmly commit to the location of Germany and invests further in the future.

The European Commission also recognizes the importance of the pharmaceutical industry. Just a few days ago, it presented a new pharmaceutical package. The goal is to improve access to medicines within the EU and simplify approval processes. In the upcoming discussions, we will ensure ‑ as we have already stated in our talks ‑ that research and investments for companies like yours remain worthwhile in the future. Yes, that also means protecting intellectual property. Because only then will research continue to be conducted here in Europe in the interest of patients.

Ladies and gentlemen, "Will this all turn out well?" I am often asked this when I speak with citizens in the country these days – with the war in Ukraine, with the energy transition, with all the changes we are experiencing. My answer is always: It can and it will turn out well because we are a strong country, with citizens who take action, and with innovative companies like yours, because we have set clear goals, because we are breaking down barriers and now investing billions in the future, and because we are pulling together ‑ companies, employees, the federal government, states, cities, and municipalities. When I say this again in the future, I will think of Ingelheim, of how the signs here, as in many other places in Germany, point to a new beginning and how good that is for our country.

Thank you very much!